Geron Corporation (GERN)
Stock Price:
$1.85 USD
-0.04 (-1.86%)
Updated Oct 20, 2020 10:42 AM EDT - Market open
Key Info
| Market Cap |
572.81M |
| Revenue (ttm) |
397,000 |
| Net Income (ttm) |
-76.43M |
| Shares Out |
310.47M |
| EPS (ttm) |
-0.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$1.85 |
| Previous Close |
$1.88 |
| Change ($) |
-0.04 |
| Change (%) |
-1.86% |
| Day's Open |
1.89 |
| Day's Range |
1.84 - 1.91 |
| Day's Volume |
374,144 |
| 52-Week Range |
0.75 - 2.40 |
More Stats
| Market Cap |
572.81M |
| Enterprise Value |
359.55M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
310.47M |
| Float |
292.57M |
| EPS (basic) |
-0.37 |
| EPS (diluted) |
-0.37 |
| FCF / Share |
-0.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
44.18M |
| Short Ratio |
12.59 |
| Short % of Float |
15.10% |
| Beta |
1.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,442.85 |
| PB Ratio |
2.39 |
| Revenue |
397,000 |
| Operating Income |
-79.64M |
| Net Income |
-76.43M |
| Free Cash Flow |
-61.67M |
| Net Cash |
213.26M |
| Net Cash / Share |
0.69 |
| Gross Margin |
-9,774.06% |
| Operating Margin |
-20,059.45% |
| Profit Margin |
-19,251.60% |
| FCF Margin |
-15,533.25% |
| ROA |
-22.56% |
| ROE |
-37.49% |
| ROIC |
-50.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.00*
(116.80% upside)
Low
3.00
Current: $1.85
High
7.00
Target: 4.00
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.46 | 1.07 | 1.07 | 6.16 | 36.37 | 1.15 | 1.28 | 2.71 | 2.44 | 3.56 |
| Revenue Growth | -56.85% | 0.09% | -82.72% | -83.06% | 3054.47% | -10.13% | -52.64% | 11.12% | -31.57% | - |
| Gross Profit | 0.46 | 1.07 | 1.07 | 6.16 | 36.37 | 1.15 | 1.28 | 2.71 | 2.44 | 3.56 |
| Operating Income | -72.57 | -29.77 | -29.33 | -30.73 | -0.56 | -36.31 | -38.96 | -71.76 | -96.12 | -111 |
| Net Income | -68.55 | -27.02 | -27.92 | -29.54 | 0.05 | -35.67 | -38.38 | -68.88 | -96.85 | -111 |
| Shares Outstanding | 190 | 177 | 159 | 159 | 158 | 154 | 128 | 127 | 125 | 97.60 |
| Earnings Per Share | -0.36 | -0.15 | -0.18 | -0.19 | - | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 |
| Operating Cash Flow | -43.83 | -21.01 | -20.56 | -18.37 | -24.20 | 9.35 | -36.68 | -55.15 | -62.39 | -44.29 |
| Capital Expenditures | -0.41 | -0.02 | - | -0.04 | -0.09 | -0.13 | 1.19 | -0.69 | -0.61 | -0.83 |
| Free Cash Flow | -44.24 | -21.03 | -20.56 | -18.41 | -24.29 | 9.22 | -35.49 | -55.84 | -63.00 | -45.13 |
| Cash & Equivalents | 140 | 164 | 94.95 | 115 | 114 | 152 | 66.02 | 96.33 | 122 | 187 |
| Total Debt | 2.55 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 137 | 164 | 94.95 | 115 | 114 | 152 | 66.02 | 96.33 | 122 | 187 |
| Assets | 166 | 185 | 110 | 130 | 149 | 173 | 67.34 | 99.80 | 160 | 234 |
| Liabilities | 30.36 | 7.55 | 6.52 | 7.87 | 6.63 | 41.80 | 7.59 | 14.15 | 13.44 | 40.85 |
| Book Value | 135 | 178 | 104 | 122 | 142 | 131 | 59.76 | 85.65 | 147 | 193 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Geron Corporation |
| Country |
United States |
| Employees |
45 |
| CEO |
John A. Scarlett |
Stock Information
| Ticker Symbol |
GERN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GERN |
| IPO Date |
June 30, 1996 |
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.